For almost four decades, Janet Woodcock has served in nearly every major leadership position at the FDA — acting commissioner, deputy commissioner, CDER director, Office of New Drugs director, COO and more.
Woodcock officially retires on Wednesday and sat down with Endpoints News via video conference to talk about how she would reform the advisory committee system, why we’re not ready for the next pandemic, and what she would’ve done differently with Sarepta’s accelerated approval for Exondys 51 (eteplirsen) in 2016.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.